Profile: Danaher Corp (DHR.N)
9 Dec 2016
Danaher Corporation (Danaher), incorporated on October 3, 1986, is a global science and technology company. The Company's research and development, manufacturing, sales, distribution, service and administrative facilities are located in approximately 50 countries. The Company's segments include Environmental; Life Sciences & Diagnostics, and Dental. The Company's product identification business develops and manufactures equipment, consumables and software for various printing, marking, coding, design and color management applications on consumer and industrial products. Its product identification products are marketed under the ESKO, FOBA, LINX, PANTONE, VIDEOJET and X-RITE brands. Its manufacturing facilities are located in North America, Europe, South America and Asia.
The Company's Environmental segment's products and services help protect the global water supply, facilitate environmental stewardship and provide the safety of personal data. The Company's Environmental segment consists of water quality business. Danaher's water quality business provides instrumentation and disinfection systems to help analyze, treat and manage the quality of ultra-pure, potable, waste, ground and ocean water in residential, commercial, industrial and natural resource applications. Its water quality business designs, manufactures and markets a range of analytical instruments, software and related consumables and services that detect and measure chemical, physical, and microbiological parameters in ultra-pure, potable, waste, ground and ocean water; ultraviolet disinfection systems, which disinfect billions of gallons of municipal, industrial and consumer water every day in over 35 countries, and industrial water treatment solutions, including chemical treatment solutions intended to address corrosion, scaling and biological growth problems in boiler, cooling water and industrial wastewater applications, as well as associated analytical services.
The Company provides its products and services to professionals in municipal drinking water and wastewater treatment plants and industrial process water and wastewater treatment facilities, third-party testing laboratories and environmental field operations. The Company's water quality business provides products under a range of brands, including CHEMTREAT, HACH, HACH/LANGE, MCCROMETER and TROJAN TECHNOLOGIES. Its manufacturing facilities are located in North America, Europe, Asia and Latin America.
The Company's telematics products include vehicle tracking and fleet management hardware and software solutions that fleet managers use to position and dispatch vehicles, manage fuel consumption and promote vehicle safety, compliance, operating efficiency and productivity. Typical users of these solutions span a range of industries and include businesses and other organizations that manage vehicle fleets. Its telematics products are marketed under a range of brands, including NAVMAN WIRELESS and TELETRAC. Its manufacturing facilities are located in North America, Europe, Asia and South America.
Life Sciences & Diagnostics
The Company's diagnostics business offers analytical instruments, reagents, consumables, software and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The Company's life sciences business offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. Its diagnostics business is also a provider of filtration, separation and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics and general industrial segments. The diagnostics business consists of its clinical laboratory (or clinical lab), critical care and anatomical pathology diagnostics businesses.
The Company's clinical lab business is a manufacturer and marketer of biomedical testing instrument systems, tests and supplies that are used to evaluate and analyze samples made up of body fluids, cells and other substances. The information generated is used to diagnose disease, monitor and guide treatment and therapy, assist in managing chronic disease and assess patient status in hospital, outpatient and physicians' office settings. The Company's chemistry systems use electrochemical detection and chemical reactions with patient samples to detect and quantify substances of diagnostic interest in blood, urine and other body fluids. Its commonly performed tests include glucose, cholesterol, triglycerides, electrolytes, proteins and enzymes, as well as tests to detect urinary tract infections and kidney and bladder disease. The Company's immunoassay systems also detect and quantify chemical substances of diagnostic interest in body fluids, particularly in circumstances where more specialized diagnosis is required.
The Company's cellular analysis business includes hematology and flow cytometry products. The business' hematology systems use principles of physics, optics, electronics and chemistry to separate cells of diagnostic interest and then quantify and characterize them, allowing clinicians to study formed elements in blood (such as red and white blood cells and platelets). The business' flow cytometry products sort, identify, categorize and characterize multiple types of cells in suspension, allowing clinicians to determine cell types and characteristics and analyze specific cell populations based on molecular differences.
The Company's microbiology systems are used for the identification of bacteria and antibiotic susceptibility testing (ID/AST) from human clinical samples, to detect and quantify bacteria related to microbial infections in urine, blood, and other body fluids, and to detect infections, such as urinary tract infections, pneumonia and wound infections. The Company's technology enables direct testing of clinical isolates to ensure reliable detection of resistance to antibiotics. The Company also offers systems and workflow solutions that allow laboratories to automate a number of steps from the pre-analytical through post-analytical stages, including sample barcoding/information tracking, centrifugation, aliquotting, storage and conveyance. Its systems along with the analyzers are controlled through laboratory level software that enables laboratory managers to monitor samples, results and lab efficiency. The Company provides its products to hospitals, physician's offices, veterinary laboratories, reference laboratories and pharmaceutical clinical trial laboratories.
The Company's critical care diagnostics business is a provider of instruments, software and related consumables and services that are used in both laboratory and point-of-care environments to measure critical parameters, including blood gases, electrolytes, metabolites and cardiac markers, as well as for anemia and high-sensitivity glucose testing. Typical users of these products include hospital central laboratories, intensive care units, hospital operating rooms, hospital emergency rooms, physician's office laboratories and blood banks. The Company's anatomical pathology diagnostics business is a company in the anatomical pathology market, offering a suite of instrumentation and related consumables used across the entire workflow of a pathology laboratory. Its anatomical pathology diagnostics products include minimally invasive, vacuum-assisted breast biopsy instruments; tissue embedding, processing and slicing (microtomes) instruments and related reagents and consumables; chemical and immuno-staining instruments, reagents, antibodies and consumables; slide coverslipping and slide/cassette marking instruments, and imaging instrumentation including slide scanners, microscopes, cameras and software solutions to store, share and analyze pathology images digitally. Typical users of these products include pathologists, lab managers and researchers. Its diagnostics business generally markets its products under the APERIO, BECKMAN COULTER, HEMOCUE, IRIS, LEICA BIOSYSTEMS, MAMMATOME, RADIOMETER and SURGIPATH brands. Its manufacturing facilities are located in North America, Europe, Asia and Australia.
The Company's life sciences business consists of various businesses, including microscopy, mass spectrometry and filtration. The Company's microscopy business is a provider of professional microscopes designed to manipulate, preserve and capture images of and enhance the user's visualization and analysis of microscopic structures. Its microscopy products include laser scanning (confocal) microscopes; compound microscopes and related equipment; surgical and other stereo microscopes, and specimen preparation products for electron microscopy. Typical users of these products include research, medical and surgical professionals operating in research and pathology laboratories, academic settings and surgical theaters. The Company through its Pall Corporation (Pall) business is also a provider of products used to remove solid, liquid and gaseous contaminants from a range of liquids and gases, consisting primarily of filtration consumables and to a lesser extent systems that incorporate filtration consumables and associated hardware.
The Company's mass spectrometry business is a provider of high-end mass spectrometers. The Company's mass spectrometer systems are used in various applications, such as drug discovery and clinical development of therapeutics, as well as in basic research, clinical testing, food and beverage quality testing and environmental testing. It also provides bioanalytical measurement systems, including microplate readers, automated cellular screening products and associated reagents, and imaging software. It also offers workflow instruments and consumables that help researchers analyze genomic, protein and cellular information. Its product areas include sample preparation equipment, such as centrifugation and capillary electrophoresis instrumentation and consumables; liquid handling automation instruments and associated consumables; flow cytometry instrumentation and associated antibodies and reagents, and particle characterization instrumentation. Its life sciences business generally markets its products under the BECKMAN COULTER, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL and SCIEX brands. Its manufacturing facilities are located in Europe, Australia, Asia and North America. The business sells to customers through direct sales personnel and independent distributors.
The Company's Dental segment provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone. The Company is a provider of a range of dental consumables, equipment and services. Its dental businesses develop, manufacture and market various dental consumables and dental equipment, such as implant systems and dental prosthetics; orthodontic bracket systems and lab products; endodontic systems and related consumables; restorative materials and instruments, including rotary burrs, impression materials, bonding agents and cements; infection prevention products; digital imaging systems and software and other visualization and magnification systems; air and electric handpieces and associated consumables, and treatment units. Its customers and users include general dentists, dental specialists, dental hygienists, dental laboratories and other oral health professionals, as well as educational, medical and governmental entities. Its dental products are marketed primarily under the DEXIS, GENDEX, iCAT, IMPLANT DIRECT, INSTRUMENTARIUM DENTAL, KAVO, KERR, NOBEL BIOCARE, ORMCO, PELTON & CRANE, PENTRON, SOREDEX, SYBRON ENDO and TOTAL CARE brands. Its manufacturing facilities are located in Europe, North America, South America and Asia.
2200 Pennsylvania Ave NW Ste 800
WASHINGTON DC 20037-1731
Company Web Links
- BRIEF-Danaher enters new $3 bln 364-day revolving credit facility
- BRIEF-Cepheid receives required regulatory clearances in proposed acquisition by Danaher
- BRIEF-Danaher reports Q3 earnings per share $0.57
- BRIEF-S&P places Danaher Corp. 'A' ratings on watch negative on planned acqusition of Cepheid
- Danaher to buy Cepheid in $4 billion deal to expand in diagnostics